The effects of levofloxacin on ECG parameters and late potentials

American Journal of Therapeutics

Volumn 12, Issue 5, 2005, Pages 407-410

  Basyigit, Ilknur ^a   Kahraman, Goksel ^a   Ilgazli, Ahmet ^a   Yildiz, Fusun ^a   Boyaci, Hasim ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

ECG; Heart rate; Late potentials; Levofloxacin; QT

Indexed keywords

LEVOFLOXACIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG EFFECT; DRUG INFUSION; ELECTRICAL POTENTIAL PARAMETERS; ELECTROCARDIOGRAM; FEMALE; HEART ARRHYTHMIA; HEART MUSCLE POTENTIAL; HEART RATE; HUMAN; MALE; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; SINGLE DRUG DOSE; TACHYCARDIA;

AGE FACTORS; ANTI-BACTERIAL AGENTS; ARRHYTHMIA; COMMUNITY-ACQUIRED INFECTIONS; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OFLOXACIN; PNEUMONIA, BACTERIAL;

EID: 26844559646     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000127358.38755.c5     Document Type: Article

References (22)

1. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730-1754.
2. Owens RC, Ambrose PG. Torsade de pointes associated with fluoroquinolones. Pharmacotherapy. 2002;22:663-668.
3. Paltoo B, O'Donoghue S, Mousavi MS. Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval. Pacing Clin Electrophysiol. 2001;24:895-897.
4. Yildiz P, Tükek T, Akkaya V, et al. Ventricular arrhythmias in patients with COPD are associated with QT dispersion. Chest. 2002;122:2055-2061.
5. Noel GJ, Natarajan J, Chien S, et al. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther. 2003;73:292-303.
6. Breithard G, Cain ME, El-Sherif N, et al. Standards for analysis of ventricular late potentials using high-resolution or signal-averaged electrocardiography. A statement by a task force committee of the European Society of Cardiology, the American Heart Association and the American Collage of Cardiology. Eur Heart J. 1991;12: 473-480.
7. Iannini PB. Cardiotoxicity of macrolides. Ketolides and fluoroquinolones that prolong QT interval. Expert Opin Drug Saf. 2002;1:121-128.
8. Mishra A, Friedman HS, Sinha AK. The effects of erythromycin on the electrocardiogram. Chest. 1999;115: 983-986.
9. Ohtani H, Taninaka C, Hanada E, et al. Comparative pharmacodynamic analysis of QT interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. Antimicrob Agents Chemother. 2000;44:2630-2637.
10. Hayashi Y, Ikeda U, Hashimoto T, et al. Torsade de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. Pacing Clin Electrophysiol. 1999;22:672-674.
11. Wimer SM, Schoonover L, Garrison MW. Levofloxacin: a therapeutic review. Clin Ther. 1998;20:1049-1070.
12. Adamantidis MM, Dumotier BM, Caron JF, et al. Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers. Fundament Clin Pharmacol. 1998;12:70-76.
13. Yap YG, Camm J. Risk of torsade de pointes with non-cardiac drugs. BMJ. 2000;320:1158-1159.
14. Chiba K, Sugiyama A, Satoh Y, et al. Proarrhythmic effects of fluoroquinolone antibacterial agents: in vivo effects as physiologic substrate for torsades. Toxicol Appl Pharmacol. 2000;169:8-16.
15. Kahn JB. Latest industry information on the safety profile of levofloxacin in the US. Chemotherapy. 2001;47:32-37.
16. Samaha FF. QTc interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin. Am J Med. 1999;107:528-529.
17. Curtis LH, Ostbye T, Sendersky V. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med. 2003;114:135-141.
18. Iannini PB, Doddamani S, Byazrova E, et al. Risk of torsade de pointes with non-cardiac drugs. Prolongation of QT interval probably a class effect of fluoroquinolones. BMJ. 2001;322:46-47.
19. Frothingham R. Rates of torsade de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy. 2001;21:1468-1472.
20. Steinberg JS, Berbari EJ. The signal-averaged electrocardiogram: update on clinical applications. J Cardiovasc Electrophysiol. 1996;7:972-988.
21. Mladosievicova B, Foltinova A, Bernadic M, et al. Signal-averaged ECG in patients after anthracycline therapy for childhood cancer. Neoplasma. 1998;45:40-45.
22. Stahlmann R, Lode H. Fluoroquinolones in the elderly: safety considerations. Drugs Aging. 2003;20:289-302.